Evans syndrome occurring against a background of common variable immunodeficiency (CVID) presents a distinct clinical challenge. The underlying primary immunodeficiency must be factored into every therapeutic decision.
Clinical scenario: Evans syndrome in a patient with common variable immunodeficiency — a primary antibody deficiency that shapes treatment selection and the safety profile of subsequent management options.
Treatment approach (partial): The initial strategy follows a corticosteroid-based approach as first-line treatment, broadly consistent with the management of Evans syndrome in other settings — though the CVID context determines what comes next. The complete, sequenced regimen is available via the link below.
For SLE or CVID-associated ES, the initial strategy is similar to the one of the primary ES, rituximab being a good corticosteroid-sparing 2nd line option while splenectomy is not recommended in those settings.
When rituximab is given for treating a patient with ES who has an underlying CVID, replacement therapy with subcutaneous Ig must be systematic to avoid severe infections.
View source ↗